/
Inspira Technologies Oxy B.H.N. Ltd. is a medical technology company specializing in the development of innovative respiratory support solutions. Its primary focus is on improving the range of possible treatments for acute respiratory failure, a severe and immediate health concern that impacts numerous patients worldwide. The company's flagship product is a minimally invasive blood oxygenation device designed to allow patients to remain conscious and mobile, unlike traditional mechanical ventilation. By targeting the healthcare sector, particularly hospitals and emergency facilities, Inspira Technologies aims to enhance respiratory care standards and patient outcomes. The company's technology has garnered attention for its potential to transform respiratory support, making it significant in markets where there is a demand for advanced health-tech solutions. As such, it plays a crucial role in addressing both the technological and operational needs of the modern medical environment.
$1.27
$0.07 (-5.22%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-4713.84% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -153.56% to -276.66%, capital efficiency is deteriorating. Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$289K
Net Income (TTM)
-$13M
▼ -19.6% YoY
Op. Margin
-4713.84%
ROIC
-276.66%
▼ -123.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -4.5% YoY
Op. Cash Flow (TTM)
-$9M
▲ +4.4% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
Continue Research
Inspira Technologies Oxy B.H.N. (IINN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Inspira Technologies Oxy B.H.N. scores 10/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Inspira Technologies Oxy B.H.N. scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -4,713.8% operating margin and a -276.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh IINN's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.